Delivery Order SPE2DB22D3501-SPE2DB25FUS88

Award Date 2/27/25
Potential Completion Date 2/28/25
Potential Value $1.4K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,902.66 Firm Fixed Price delivery order is for the supply of VYVANSE 20 MG CAPSULE 100S, a pharmaceutical product. The contract has an ultimate completion date of February 25, 2025. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which...
This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, is a Delivery Order valued at $1,567.13 to provide VYVANSE 30 MG CAPSULE 100S to the Defense Logistics Agency (DLA). The contract has an ultimate completion date of November 27, 2024 and is a Firm Fixed Price arrangement. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 through November 2026, which serves as a primary...
The U.S. Defense Logistics Agency (DLA) Troop Support Medical has awarded a firm fixed price delivery order contract to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation, a leading global pharmaceutical distributor. The $1,667.38 contract is to provide 4564222091 VYVANSE 30 MG CAPSULE 100S, a pharmaceutical product, to the agency. This delivery order is part of a larger indefinite delivery contract (IDC) valued at up to $999,999,999.00, which serves as the primary...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,635.68 firm fixed-price delivery order is for the supply of VYVANSE 70 MG CAPSULE 100S, a pharmaceutical product. The contract has an ultimate completion date of February 10, 2025. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which...
This is a federal contract award to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, by the Defense Logistics Agency (DLA) Troop Support Medical. The $2,343.49 firm fixed-price delivery order is for the supply of 4,563,886,982 units of VYVANSE 10 MG CAPSULE 100S. The contract has an ultimate completion date of March 8, 2024. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,337.70 fixed-price delivery order is for the supply of VYVANSE 30 MG CAPSULE 100S, a pharmaceutical product. The contract has an ultimate completion date of January 6, 2025. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,660.67 Firm Fixed Price Delivery Order contract is for the supply of 4567394215 ! VYVANSE 70 MG CAPSULE 100S. The contract has an ultimate completion date of February 27, 2025. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as...
The U.S. Defense Logistics Agency (DLA) awarded a Firm Fixed Price Delivery Order contract worth $2,892.27 to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of 100 units of the medication VYVANSE 70 mg capsules. This award is part of a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. The IDC serves...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract worth $1,403.54 to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation. The contract is to provide 4,564,015,246 units of the drug VYVANSE 30 MG CAPSULE 100S. This delivery order is part of a larger, single-award indefinite delivery contract (IDC) awarded to Amerisourcebergen Drug Corp, valued at up to $999,999,999.00 and running through December 31, 2025. The IDC serves as the...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $8,505.72 firm fixed-price delivery order contract is for the provision of 4564909224 - VYVANSE 40 MG CAPSULE 100S. The contract has an ultimate completion date of June 17, 2024. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary...
  • SPE2DB22D3501
    Indefinite Delivery Contract
  • SPE2DB22D3501-SPE2DB25FUS88
    Delivery Order

The U.S. Defense Logistics Agency (DLA) awarded a Firm Fixed Price Delivery Order contract worth $1,358.10 to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of 4567410765 VYVANSE 30 MG CAPSULE 100S and has a completion date of February 28, 2025. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued at $999,999,999 through November 2026, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. This award does not have a set-aside designation, indicating open competition.

Generated 6/1/25, 2:55 AM